Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: evaluation report 2

01.  NICE’s response to comments on the Appraisal Consultation Document (ACD)

02.  Consultee comments on the ACD – Cell Therapeutics

03.  Consulttee comments on the ACD – Cell Therapeutics

04.  Consultee comments on the ACD – Cell Therapeutics

05.  Consultee comments on the ACD – Lymphoma Association

06.  Clinical expert comments on the ACD – McMillan

07.  Evidence Review Group critique of manufacturer PAS submission prepared by BMJ Group

* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *